Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

BMC Women's Health

Volumn 8, Issue , 2008, Pages

  Foster, Shonda A ^a   Foley, Kathleen A ^b   Meadows, Eric S ^a   Johnston, Joseph A ^a   Wang, Sara ^b   Pohl, Gerhardt M ^a   Long, Stacey R ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; RALOXIFENE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE DENSITY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; URBAN AREA; AGED; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; INSURANCE; MEDICAID; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATIENT SELECTION; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

AGED; BONE DENSITY CONSERVATION AGENTS; CHI-SQUARE DISTRIBUTION; DIPHOSPHONATES; FEMALE; HUMANS; INSURANCE CLAIM REPORTING; LOGISTIC MODELS; MEDICAID; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; RALOXIFENE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; UNITED STATES;

EID: 60949103475     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-8-24     Document Type: Article

References (22)

1. U.S. Department of Health and Human Services Bone Health and Osteoporosis: A Report of the Surgeon General Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
2. Osteoporosis prevention, diagnosis, and therapy NIH Consens Statement 2000, 17:1-45.
3. Riggs BL Melton LJ The worldwide problem of osteoporosis: Insights afforded by epidemiology Bone 1995, 17:505S-511S. 10.1016/ 8756-3282(95)00258-4 8573428
4. Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Gluer CC Krueger K Cohen FJ Eckert S Ensrud KE Avioli LV Lips P Cummings SR for the Multiple Outcomes of Raloxifene Evaluation Investigators Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 1999, 282:637-645. 10.1001/jama.282.7.637 10517716
5. Delmas PD Ensrud KE Adachi JD Harper KD Sarkar S Gennari C Reginster J Pols HA Recker RR Harris ST Wu Wentao Genant HK Black DM Eastell R Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial J Clin Endocrinol Metab 2002, 87:3609-3617. 10.1210/jc.87.8.3609 12161484
6. Sambrook PN Geusens P Ribot C Solimano JA Ferrer-Barriendos J Gaines K Verbruggen N Melton ME Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of FOSAMAX® versus EVISTA® Comparison Trial) International J Intern Med 2004, 255:503-511. 10.1111/j.1365-2796.2004.01317.x 15049885
7. Harris ST Watts NB Genant HK McKeever CD Hangartner T Keller M Chesnut CH Brown J Eriksen EF Hoseyni MS Axelrod DW Miller PD for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial JAMA 1999, 282:1344-1352. 10.1001/jama.282.14.1344 10527181
8. Lufkin EG Wong M Deal C The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis Rheum Dis Clin North Am 2001, 27:163-185. 10.1016/S0889-857X(05)70192-7 11285993
9. Martino S Cauley JA Barrett-Connor E Powles TJ Mershon J Disch D Secrest RJ Cummings SR for the CORE investigators Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004, 96:1751-1761. 15572757
10. Martino S Disch D Dowsett SA Keech CA Mershon JL Safety assessment of raloxifene over eight years in a clinical trial setting Curr Med Res Opin 2005, 21:1441-1452. 10.1185/030079905X61839 16197663
11. Vogel VG Costantino JP Wickerham DL Cronin WM Cecchini RS Atkins JN Bevers TB Fehrenbacher L Pajon ER Wade JL Robidoux A Margolese RG James J Lippman SM Runowicz CD Ganz PA Reis SE McCaskill-Stevens W Ford LG Jordan C Wolmark N for the National Surgical Adjuvant Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006, 295:2727-2741. 10.1001/jama.295.23.joc60074 16754727
12. Barrett-Connor E Mosca L Collins P Geiger MJ Grady D Kornitzer M McNabb MA Wenger NK Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006, 355:125-137. 10.1056/ NEJMoa062462 16837676
13. Raloxifene (Evista) product label Eli Lilly and Company, Indianapolis; 2007.
14. Kleerekoper M Schein JR Comparative safety of bone remodeling agents with a focus on osteoporosis therapy J Clin Pharmacol 2001, 41:239-250. 10.1177/00912700122010050 11269564
15. Bamias A Kastritis E Bamia C Moulopoulos LA Melakopoulos I Bozas G Koutsoukou V Gika D Anagnostopoulos A Papadimitriou C Terpos E Dimopoulos MA Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors J Clin Onco 2005, 23:8580-8587. 10.1200/JCO.2005.02.8670
16. Ibandronate (Boniva) product label Roche GlaxoSmithKlein, Nutley, NJ; 2005.
17. Alendronate (Fosamax) product label Merck & Co, Inc., Whitehouse Station, NJ; 2005.
18. Risedronate (Actonel) product label Proctor & Gamble Pharmaceuticals, Cincinnati, OH; 45202 2005.
19. HEDIS Guidelines http://www.ncqa.org Accessed August 9, 2005.
20. Deyo RA Cherkin DC Ciol MA Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 1992, 45:613-19. 10.1016/0895-4356(92)90133-8 1607900
21. Cadarette SM Katz JN Brookhart A Sturmer T Stedman MR Solomon DH Relative effectiveness of osteoporosis drugs for preventing nonvertebral fractures Ann Intern Med 2008, 148:637-46. 18458276
22. Birnbaum HG Cremieux PY Greenberg PG LeLorier J Ostrander J Venditti L Using healthcare claims data for outcomes research and pharmacoeconomic analysis Pharmacoeconomics 1999, 16:1-8. 10.2165/ 00019053-199916010-00001 10539118